CN117771354A - 一种预防O型口蹄疫的mRNA-LNP疫苗及其制备方法 - Google Patents
一种预防O型口蹄疫的mRNA-LNP疫苗及其制备方法 Download PDFInfo
- Publication number
- CN117771354A CN117771354A CN202410199491.0A CN202410199491A CN117771354A CN 117771354 A CN117771354 A CN 117771354A CN 202410199491 A CN202410199491 A CN 202410199491A CN 117771354 A CN117771354 A CN 117771354A
- Authority
- CN
- China
- Prior art keywords
- mrna
- mouth disease
- sequence
- vaccine
- foot
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000710198 Foot-and-mouth disease virus Species 0.000 title claims abstract description 78
- 229960005486 vaccine Drugs 0.000 title claims abstract description 67
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 title claims abstract description 61
- 238000002360 preparation method Methods 0.000 title abstract description 14
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 49
- 238000000338 in vitro Methods 0.000 claims abstract description 15
- 150000002632 lipids Chemical class 0.000 claims abstract description 13
- 239000002105 nanoparticle Substances 0.000 claims abstract description 12
- 239000002773 nucleotide Substances 0.000 claims abstract description 7
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 7
- 102000036639 antigens Human genes 0.000 claims description 18
- 108091007433 antigens Proteins 0.000 claims description 18
- 239000000427 antigen Substances 0.000 claims description 17
- 239000013612 plasmid Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 238000000746 purification Methods 0.000 claims description 12
- 238000013518 transcription Methods 0.000 claims description 9
- 230000035897 transcription Effects 0.000 claims description 9
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims description 8
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 7
- 241000701533 Escherichia virus T4 Species 0.000 claims description 6
- 102000009123 Fibrin Human genes 0.000 claims description 6
- 108010073385 Fibrin Proteins 0.000 claims description 6
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 6
- 229950003499 fibrin Drugs 0.000 claims description 6
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 239000013638 trimer Substances 0.000 claims description 3
- 239000013598 vector Substances 0.000 claims description 3
- 241000700199 Cavia porcellus Species 0.000 abstract description 20
- 210000004698 lymphocyte Anatomy 0.000 abstract description 20
- 210000000952 spleen Anatomy 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 11
- 238000013461 design Methods 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 6
- 208000035473 Communicable disease Diseases 0.000 abstract description 5
- 238000002474 experimental method Methods 0.000 abstract description 5
- 238000001727 in vivo Methods 0.000 abstract description 4
- 208000015181 infectious disease Diseases 0.000 abstract description 4
- 230000001154 acute effect Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 3
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 abstract description 2
- 230000003211 malignant effect Effects 0.000 abstract description 2
- 229940023146 nucleic acid vaccine Drugs 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 description 17
- 229940031551 inactivated vaccine Drugs 0.000 description 15
- 241000700605 Viruses Species 0.000 description 14
- 241000700198 Cavia Species 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 238000011160 research Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 208000032843 Hemorrhage Diseases 0.000 description 7
- 230000004727 humoral immunity Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 230000008595 infiltration Effects 0.000 description 7
- 238000001764 infiltration Methods 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 230000007969 cellular immunity Effects 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 210000004969 inflammatory cell Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000003472 neutralizing effect Effects 0.000 description 6
- 210000004940 nucleus Anatomy 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 210000005229 liver cell Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 108010041986 DNA Vaccines Proteins 0.000 description 3
- 229940021995 DNA vaccine Drugs 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 229960000074 biopharmaceutical Drugs 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 2
- 241000710194 Foot-and-mouth disease virus - type O Species 0.000 description 2
- 206010024642 Listless Diseases 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 241000425262 Tai virus Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 208000017971 listlessness Diseases 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000003456 pulmonary alveoli Anatomy 0.000 description 2
- 210000003314 quadriceps muscle Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000220451 Canavalia Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101710177112 Hemoglobin subunit alpha-1 Proteins 0.000 description 1
- 101000640813 Homo sapiens Sodium-coupled neutral amino acid transporter 2 Proteins 0.000 description 1
- 101000716973 Homo sapiens Thialysine N-epsilon-acetyltransferase Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 229940022005 RNA vaccine Drugs 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000019229 Spleen disease Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241001493546 Suina Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102100020926 Thialysine N-epsilon-acetyltransferase Human genes 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 241000907316 Zika virus Species 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007440 host cell apoptosis Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 101150044508 key gene Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- -1 kozak sequence Proteins 0.000 description 1
- 208000030175 lameness Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000149 liver necrosis Toxicity 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 108700021021 mRNA Vaccine Proteins 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000004177 patent blue V Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410199491.0A CN117771354B (zh) | 2024-02-23 | 一种预防O型口蹄疫的mRNA-LNP疫苗及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410199491.0A CN117771354B (zh) | 2024-02-23 | 一种预防O型口蹄疫的mRNA-LNP疫苗及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117771354A true CN117771354A (zh) | 2024-03-29 |
CN117771354B CN117771354B (zh) | 2024-07-05 |
Family
ID=
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020076405A1 (en) * | 1999-04-15 | 2002-06-20 | Xie Yong | Antigenized antibody vaccine for foot-and-mouth disease |
US20050202024A1 (en) * | 1999-04-15 | 2005-09-15 | Hong Kong University Of Science & Technology | Protein sequences containing antigenized antibodies for foot-and-mouth disease |
US20100129402A1 (en) * | 2007-05-28 | 2010-05-27 | Jixing Liu | Double-effective vaccine vector against foot-and-mouth disease virus (fmdv), methods of preparing and using the same |
RU2010131315A (ru) * | 2010-07-26 | 2012-02-10 | Федеральное государственное учреждение "Федеральный центр охраны здоровья животных" (ФГУ "ВНИИЗЖ") (RU) | Штамм а 2045/киргизия/ 2007 вируса ящура aphtae epizooticae типа а для контроля антигенной и иммуногенной активности противоящурных вакцин и для изготовления биопрепаратов для диагностики и специфической профилактики ящура типа а |
KR20130078265A (ko) * | 2011-12-30 | 2013-07-10 | 대한민국(관리부서 : 농림축산식품부 농림축산검역본부) | 감염력이 있는 구제역바이러스 O형 cDNA 클론 및 클론의 전체염기서열 |
CN113164561A (zh) * | 2018-09-13 | 2021-07-23 | 摩登纳特斯有限公司 | 用于治疗糖原贮积病的编码葡萄糖-6-磷酸酶的多核苷酸 |
US20220017576A1 (en) * | 2020-07-14 | 2022-01-20 | Lanzhou Veterinary Research Institute, Chinese Academy Of Agricultural Sciences | Recombinant foot-and-mouth disease virus with reduced immunosuppression activity, and preparation method and use thereof |
US20230149529A1 (en) * | 2020-04-29 | 2023-05-18 | Pulike Biological Engineering, Inc. | Foot-and-mouth disease virus-like particle antigen, vaccine composition, preparation method, and use thereof |
CN116159133A (zh) * | 2022-09-15 | 2023-05-26 | 中农威特生物科技股份有限公司 | 一种猪A型口蹄疫mRNA疫苗及其制备方法 |
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020076405A1 (en) * | 1999-04-15 | 2002-06-20 | Xie Yong | Antigenized antibody vaccine for foot-and-mouth disease |
US20050202024A1 (en) * | 1999-04-15 | 2005-09-15 | Hong Kong University Of Science & Technology | Protein sequences containing antigenized antibodies for foot-and-mouth disease |
US20100129402A1 (en) * | 2007-05-28 | 2010-05-27 | Jixing Liu | Double-effective vaccine vector against foot-and-mouth disease virus (fmdv), methods of preparing and using the same |
RU2010131315A (ru) * | 2010-07-26 | 2012-02-10 | Федеральное государственное учреждение "Федеральный центр охраны здоровья животных" (ФГУ "ВНИИЗЖ") (RU) | Штамм а 2045/киргизия/ 2007 вируса ящура aphtae epizooticae типа а для контроля антигенной и иммуногенной активности противоящурных вакцин и для изготовления биопрепаратов для диагностики и специфической профилактики ящура типа а |
KR20130078265A (ko) * | 2011-12-30 | 2013-07-10 | 대한민국(관리부서 : 농림축산식품부 농림축산검역본부) | 감염력이 있는 구제역바이러스 O형 cDNA 클론 및 클론의 전체염기서열 |
CN113164561A (zh) * | 2018-09-13 | 2021-07-23 | 摩登纳特斯有限公司 | 用于治疗糖原贮积病的编码葡萄糖-6-磷酸酶的多核苷酸 |
US20230149529A1 (en) * | 2020-04-29 | 2023-05-18 | Pulike Biological Engineering, Inc. | Foot-and-mouth disease virus-like particle antigen, vaccine composition, preparation method, and use thereof |
US20220017576A1 (en) * | 2020-07-14 | 2022-01-20 | Lanzhou Veterinary Research Institute, Chinese Academy Of Agricultural Sciences | Recombinant foot-and-mouth disease virus with reduced immunosuppression activity, and preparation method and use thereof |
CN116159133A (zh) * | 2022-09-15 | 2023-05-26 | 中农威特生物科技股份有限公司 | 一种猪A型口蹄疫mRNA疫苗及其制备方法 |
Non-Patent Citations (5)
Title |
---|
LE T等: "mRNA Vaccine Development for Emerging Animal and Zoonotic Diseases", VIRUSES, vol. 15, no. 2, 28 February 2022 (2022-02-28), pages 401 * |
WANG W等: "Prediction of lipid nanoparticles for mRNA vaccines by the machine learning algorithm", ACTA PHARM SIN B, vol. 12, no. 6, 30 June 2022 (2022-06-30), pages 2950 - 2962 * |
李鹏;何宛伦;: "口蹄疫病毒几种新型疫苗的特点及研究进展", 中国奶牛, no. 1, 15 June 2007 (2007-06-15), pages 154 - 155 * |
杜进鑫;王永录;: "口蹄疫新型疫苗及其免疫特性研究进展", 生物技术通讯, no. 02, 15 March 2009 (2009-03-15), pages 295 - 298 * |
汤雅淇等: "抗O型口蹄疫兔化弱毒YNTBa株单克隆抗体的制备及其生物学特性鉴定", 云南畜牧兽医, no. 06, 31 December 2021 (2021-12-31), pages 10 - 13 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10124055B2 (en) | Zika virus RNA vaccines | |
EP3373965A1 (en) | Rotavirus vaccines | |
CN113736801B (zh) | mRNA及包含其的新冠病毒mRNA疫苗 | |
Zhang et al. | Single-walled carbon nanotubes as delivery vehicles enhance the immunoprotective effect of a DNA vaccine against spring viremia of carp virus in common carp | |
JP2002500502A (ja) | 合成c型肝炎遺伝子 | |
US10653769B2 (en) | iDNA vaccines and methods for using the same | |
CA2583147C (en) | Chimeric vectors | |
ZA200409861B (en) | Flexible vaccine assembly and vaccine delivery platform | |
CN110156896A (zh) | 重组口蹄疫病毒样颗粒及其制备方法和应用 | |
CN112552413B (zh) | 新型冠状病毒重组蛋白亚单位疫苗 | |
CN107432930A (zh) | 一种i群4型禽腺病毒dna疫苗及其制备方法和应用 | |
CN116390752A (zh) | 自扩增性sars-cov-2rna疫苗 | |
CN102083457B (zh) | 天花dna疫苗及其引起免疫应答的抗原 | |
CN117771354B (zh) | 一种预防O型口蹄疫的mRNA-LNP疫苗及其制备方法 | |
CN103667319B (zh) | 抗人乳头瘤病毒的三价疫苗及其制法和用途 | |
CN117771354A (zh) | 一种预防O型口蹄疫的mRNA-LNP疫苗及其制备方法 | |
CN112494643B (zh) | 一种猪csfv-pcv二联dna疫苗及其制备方法 | |
CN115820696A (zh) | 治疗性多价HPV mRNA疫苗及其制备方法 | |
CN110577922A (zh) | 一种vp19和vp28穿梭载体转基因蓝藻的构建方法及其用途 | |
CN116159133B (zh) | 一种猪A型口蹄疫mRNA疫苗及其制备方法 | |
WO2024008014A1 (zh) | 抗SARS-CoV-2或其突变体感染的药物组合物及其联合用药物 | |
CN113388641B (zh) | 一种禽4型腺病毒载体、构建方法及其减毒活疫苗和应用 | |
CN116121282B (zh) | 一种表达猫疱疹病毒蛋白的mRNA疫苗及其制备方法 | |
CN116904489B (zh) | 一种鸭坦布苏病毒核酸疫苗及应用 | |
CN112210571B (zh) | 表达iss基因的新城疫LaSota弱毒疫苗株反向遗传操作系统、其构建方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240606 Address after: 650224 Jindian Qinglongshan Community, Kunming City, Yunnan Province Applicant after: YUNNAN ANIMAL SCIENCE AND VETERINARY INSTITUTE Country or region after: China Applicant after: YUNNAN AGRICULTURAL University Address before: 650224 Jindian Qinglongshan Community, Kunming City, Yunnan Province Applicant before: YUNNAN ANIMAL SCIENCE AND VETERINARY INSTITUTE Country or region before: China |
|
GR01 | Patent grant |